Document is current
Any future updates will be listed below
-
Authors
Fredwall, Svein http://orcid.org/0000-0002-2804-5783
Allum, Yana
AlSayed, Moeenaldeen
Alves, Inês
Ben-Omran, Tawfeg
Boero, Silvio
Cormier-Daire, Valerie
Guillen-Navarro, Encarna
Irving, Melita
Lampe, Christian
Maghnie, Mohamad
Mohnike, Klaus
Mortier, Geert
Sousa, Sérgio B.
Wright, Michael
-
Funding
Funding for this research was provided by:
BioMarin Pharmaceutical
Ascendis
QED Therapeutics
Pfizer UK
Sanofi
- License Information
-
More Information
Article History
Received: 11 March 2022
Accepted: 13 August 2022
First Online: 20 August 2022
Declarations
:
: Not applicable.
: Not applicable.
: SF, YA, TBO, CL have no conflict of interest to declare. MAS has received honoraria or consultation fees from BioMarin, Sanofi-Genzyme and Takeda. IA’s patient organisation, ANDO, has received grants or research support from BioMarin, Pfizer, Ascendis, Kyowa Kirin and QED. SB has received honoraria or consultation fee from CITIEFFE. VCD has participated in clinical trials (BioMarin, QED-Propel and Pfizer) and advisory boards (BioMarin, QED-Propel and Ipsen). EGN has received honoraria or consultation fees from BioMarin. MI has received honoraria or consultation fees from BioMarin, Ascendis, QED Therapeutics, Pfizer, Sanofi, Innoskel, Kyowa Kirin, Alexion, Novo Nordisk. MM has received grants or research support from Merck and Pfizer, and honoraria or consultation fees from Novo Nordisk, Merck, Pfizer, Ascendis, BioMarin and Sandoz. KM has received honoraria and consultation fees from BioMarin and QED. GM has received honoraria or consultation fees from Pfizer and BioMarin. SBS has received grants or research support from Pfizer and Ascendis and honoraria or consultation fees from BioMarin, Ascendis and Kiowa Kirin. MW has received honoraria or consultation fees from BioMarin.
